



Progress Update on Implementation of HANSA 2

LAO-C-MOH for HANSA2 Project

December 17, 2024

Content

- Overview of the project
- Summary of project implementation
 1. Disbursement against the 1st Annual Funding Decision (AFD)
 2. Management Actions Update
 3. Health Product procurement
 4. TA procurement
 5. RSSH (Lab System Strengthening)
 6. Progress of close out of C19RM (HANSA1)
 7. Challenges incurred during implementation

Overview of HANSA2 **under GF grant**

- **Program Title:** Improving health service access to strengthen the sustainability and quality of the national TB and HIV response
- **Grant Name:** Lao-C-MOH
- **Grant Fund:** USD 17,537,388
- **Implementation Period:** 2024-2026 (3 Years period)
- **1st AFD 18 months (Jan 2024-June 2025) – USD 9,773,918.57**
 - a). Disbursed to MOH: USD 3,918,445.00
 - b). Direct payment to 3rd party: USD 3,673,126.34
 - Global Drug Facilities (GDF): USD 2,767,944.34
 - TA service providers: USD 905,182.00
 - c). Health products: USD 2,182,347.23

Disbursement Progress

Disbursed to MOH of USD 3,918,445.00

Indicative cash transfer date	Forecast amount (USD)	Detail and requirement for disbursement
19/01/2024	566,740	US\$ 487,382 relates to laboratory system strengthening activities under component 2 of HANSA 2 and US\$ 79,257.75 component 3 under HANSA 2
08/07/2024	530,640	Relates to Service and Maintenance of GeneXpert machines under component 2 of HANSA 2.
06/01/2025	1,452,243	Relates to Component 1 under HANSA 2. Subject to the submission and GF approval of a third-party verification (TPV) report for round 2 of 2024
13/01/2025	1,131,507	Relates to Component 2 under HANSA 2. Subject to the submission and GF approval of the Independent Academic Institution (IAI) report on Year 1 results.
20/01/2025	237,315	US\$ 158,057 relates to laboratory system strengthening activities under component 2 of HANSA 2 and US\$ 79,257.75 component 3 under HANSA 2 for Jan to June 2025.
Total	3,918,445	

Direct payment to 3rd party, TA

Indicative cash transfer date	Payee	Forecast amount (USD)
29/02/2024	WHO	172,570
29/02/2024	CHAI	53,500
29/02/2024	NLCE, TA	79,400
04/03/2024	UNAIDS	53,500
06/01/2025	UNAIDS	53,500
06/01/2025	CHAI	74,900
06/01/2025	NLCE, TA	79,400
20/01/2015	WHO	180,081
27.01/2025	World Bank	136,932
	Total of TA	905,182

Direct payment to GDF

Indicative cash transfer date	Forecast amount
30/06/2024	1,804,864.09
10/12/2024	141,451.25
12/05/2025	821,628
Total for GDF	2,767,944.34

Progress of disbursement	Value
Budget (2024)	5,585,013
Disbursement (2024)	3,470,946
%	62%
Budget (2025)	3,470,946
Disbursement (2025)	-
%	0%

Management Actions Update

Status	Total Actions:	10
	Completed:	6
	Pending:	4

	Management Action	IAs	Status
	Implementation readiness		
1	Contracting of CSOs	CHAS & NTC	Completed, 5 CSOs contracts completed in March 2024
2	Human resources plan with details of QMU positions, timelines, training plan and onboarding of new staff	NCLE	Completed HR plan & TOR for each position have been developed.
3	By 31 October, submit a transition plan for the GF funded staff under the QMU into the national structure to be funded with domestic funding.	NCLE	Pending ; Currently no domestic funding is in the pipeline, but NCLE will continue exploring other funding opportunities and we will update based on the timeline accordingly.
4	Cepheid the service and maintenance of GeneXpert Machine - Draft contract should include the scope of work, agreed performance indicators, details of sites/hospitals and platforms and cost-breakdown.	NCLE	Pending for contract confirmation

Management Actions Update

	Management Action	IAs	Status
	Laboratory system strengthening indicators		
5	Detailed plan of the objectives, scope of work, and costing for the activities related to LIMS. This should be accompanied by the LIMS related activities to be funded from other sources during 2024-2026.	NCLE	Pending ; LIMS SoW expansion of LIMS license and services will focus on 18 provincial hospitals plus 9 district hospitals in Khammuan Province
6	Plan on contracting the service provider for LIMS implementation in 18 provincial hospitals, LIMS license and services fee and expansion. As previously communicated, the LIMS activity will build on the work done for the Xpert Connectivity solution.	NCLE	Pending
7	HANSA 2 Global Fund grant focal point. Appoint a staff member and share the details for the appointed staff and related TORs.	NPCO	Done; contracts signed
8	Technical Assistance - The DPF should ensure that the TA contracts with the respective technical partners are prepared in accordance with the agreed on and approved Terms of Reference. The DPF should submit a Memorandum of Understanding (MoU) between the TA provider and the MoH, specifying payment schedules, financial and programmatic report submission timelines, and requesting Global Fund direct disbursements.	NPCO	Done; TA contracts signed
	Co-financing Commitment Letter		
9	Supporting documents showing the fulfillment of the total minimum co-financing commitment for period 2021-2023	DPF	Done
10	Co-financing commitment letter signed by the Ministry of Planning and Investment and the MOH specifying the commitment to fulfill a) the total minimum co-financing commitment, and b) the programmatic commitments, as stipulated in the co-	DPF	Completed, MPI commitment letter signed on May 23, 2024

Procurement Progress (Health Product)

HIV HP 2024:

- completed placing order for all HP line
- 1 non-pharma (condom & lubricant): confirm PQ; modified and confirmed arts works
- ARV & HIV determine: HP delivered

TB HP 2024:

- completed placing order for all HP line
- 1 non-pharma (x-ray): reallocated for cartridges 2025

HIV & TB HP 2025:

- Quantification exercise: done
- Procurement plan: prepared
- Under reviewing by GF

HPMT Disbursement & Forecasted	2024	2025	2026	Total	
HIV	1,360,267.30	1,157,497.41	1,115,937.78	-	3,633,702.49
TB	1,087,504.60	1,026,073.12	997,199.24	-	3,110,776.96
RSSH	580,950.00	89,238.00	44,000.00	-	714,188.00
Total	3,028,721.90	2,272,808.53	2,157,137.01	-	7,458,667.45

HIV HP	2024	2025	2026	Total
GF Total	1,360,267.30	1,157,497.41	1,115,937.78	3,633,702.49
GF HIV PHARMA	639,271.10	539,412.75	624,590.56	1,803,274.42
GF HIV NON-PHARMA	720,996.20	618,084.66	491,347.21	1,830,428.08
TB HP	2024	2025	2026	Total
GF Total	1,087,504.60	1,026,073.12	997,199.24	3,110,776.96
GF TB PHARMA	458,961.57	499,738.37	518,152.42	1,527,937.18
GF TB NON-PHARMA	628,543.03	526,334.75	479,046.82	1,697,230.02




HPMT Budget	2024	2025	2026	Total	
HIV	1,236,195.64	1,178,085.25	1,150,845.65	-	3,565,126.53
TB	1,872,362.34	895,580.94	666,883.20	-	3,434,826.48
RSSH	621,077.41	89,238.00	44,000.00	-	754,315.41
Total	3,729,635.39	2,162,904.19	1,861,728.85	-	7,754,268.43

HPMT Balance	2024	2025	2026	Total	
HIV	(124,071.66)	20,587.84	34,907.87	-	(68,575.96)
TB	784,857.74	(130,492.18)	(330,316.04)	-	324,049.52
RSSH	40,127.41	-	-	-	40,127.41
Total	700,913.49	(109,904.34)	(295,408.16)	-	295,600.98

Delivery Status of Health Product 2024

Delivery Status	Total Item	Arrival	Pending	Remark
HIV HP	22	18	4	ARV, condom
TB HP	31	5	26	LFD& SLD

Reference No.	Contract title, Description and Category	Status
HIV Center	Total Cost: HIV Center	
HIV Center	Total Cost: Pharma Products	
HIV	Pharma Section 1- Medicine HIV Prevention	
HIV-P 1.1	Lamivudine/Tenofovir 300/300mg tablet	Delivered
HIV	Pharma Section 2- Antiretroviral Medicines for HIV Treatment	
HIV-P 2.1	Dolutegravir/Lamivudine/Tenofovir 50/300/300mg tablet	Delivered
HIV-P 2.2	Abacavir/Lamivudine 600/300mg tablet	Pending
HIV-P 2.3	Abacavir/Ritonavir 300/100mg tablet	Delivered
HIV-P 2.4	Lamivudine/Tenofovir 300/300mg tablet	Delivered
HIV-P 2.5	Dolutegravir 50mg tablet	Delivered
HIV-P 2.6	Lamivudine/Zidovudine 150/300mg tablet	Delivered
HIV-P 2.9	Abacavir/Lamivudine 120/60mg dispersible scored tablet	Delivered
HIV-P 2.10	Lamivudine/Zidovudine 30/60mg dispersible tablet	Delivered
HIV-P 2.11	Dolutegravir 10mg dispersible tablet	Delivered
HIV-P 2.12	Lopinavir/Ritonavir 100/25mg tablet	Delivered
HIV-P 2.13	Zidovudine 50mg/5mL oral solution, bottle	Delivered
HIV-P 2.15	Abacavir/Lamivudine/Dolutegravir 600/300/50mg tablet	Pending
HIV Center	Total Cost: Non Pharma Products	
HIV	Non-Pharma Section 1-Health Products used in HIV Prevention Programs	
HIV-NP 1.1	Male condom 52 mm, contoured	Pending
HIV-NP 1.2	Lubricant 4 mL, water based	Pending
HIV	Non-Pharma Section 2-HIV Rapid Diagnostic Tests	
HIV-NP 2.1	HIV 1+2 - Determine Complete HIV Kit	Delivered
HIV-NP 2.2	HIV 1/2 - Bioline 3.0 Kit	Delivered
HIV-NP 2.3	HIV 1+2 - Stat-Pak HIV Kit	Delivered
HIV-NP 2.4	CHECKNOW HIV SELFTEST	Delivered
HIV-NP 2.5	Alera HIV/Syphilis Duo	Delivered
HIV	Non-Pharma Section 4-HIV-specific reagents & consumables	
HIV-NP 4.1	Digipro HIV Load Test Kit	Delivered
HIV-NP 4.2	Alere HIV/Syphilis Duo	Delivered
TB Center	Total Cost: TB Center	
TB	Total Cost: TB Pharma Products	
TB-P 1.1	Rifampicin/Isoniazid Pyrazinamide/Ethambutol 150/75/400/275mg tablet	Pending
TB-P 1.2	Rifampicin/Isoniazid 150/75mg tablet	Pending
TB-P 1.3	Rifampicin/Isoniazid/Pyrazinamide 75/50/150mg dispersible tablet	Pending
TB-P 1.4	Rifampicin/Isoniazid 75/50mg dispersible tablet	Pending
TB-P 1.5	Ethambutol 100mg dispersible tablet	Pending
TB-P 1.6	Ethambutol 400mg tablet	Pending
TB-P 1.8	Isoniazid/Rifampicin 300/300mg tablet (3BP)	Pending
TB-P 1.11	Pyrazinamide 400mg tablet	Pending
TB	Pharma Section 2- Anti-tuberculosis medicines: Treatment for Drug Resistant TB (DR-TB)	
TB-P 2.1	Bedaquiline 100mg tablet	Pending
TB-P 2.2	Bedaquiline 200mg tablet	Pending
TB-P 2.3	Linezolid 600mg tablet	Pending
TB-P 2.4	Linezolid 150mg dispersible tablet	Pending
TB-P 2.6	Clotrimazole 50mg tablet	Pending
TB-P 2.7	Morfloxacin 400mg tablet	Pending
TB-P 2.8	Morfloxacin 100mg dispersible tablet	Pending
TB-P 2.9	Levofloxacin 500mg, tablet	Pending
TB-P 2.12	Pretomanid 200mg tablet	Pending
TB-P 2.13	Delamanid 25mg tablet	Pending
TB-P 2.14	Delamanid 50mg tablet	Pending
TB-P 2.16	Cycloserine 250mg capsule	Pending
TB-P 2.17	Ethionamide 125mg dispersible tablet	Pending
TB-P 2.18	Ethionamide 250mg tablet	Pending
TB	Non Pharma Section 2-TB Molecular Testing	
TB-NP 2.1	MTBRIF ULTRA Test	Delivered
TB-NP 2.2	MTB/XDR Test	Delivered
TB-NP 2.3	MTBRIF ULTRA Test	Pending
TB-NP 2.4	MTBRIF ULTRA Test+ PSM cord	Pending
TB	Non Pharma Section 3-TB Culture	
TB-NP 3.1	BACTEC MGIT 960 System (445970)	Pending
TB-NP 3.2	BACTECmgIT Supplement Kit, PANTA and OADC combined vials (245124)	Delivered
TB-NP 3.3	BACTECmgIT Tubes 7mL (245122)	Delivered
TB-NP 3.4	BACTEC MGIT 960 System Installation and Training (01SM0001)	Pending
TB-NP 3.5	BACTEC Printer Bottle 1.5000D (257710)	Pending
TB-NP 3.6	UPS 3000VA with battery pack	Pending



Procurement Progress (TA)

No	TA	Provider	Progress
1	National program officer (TA) for HIV prevention	UNAIDS	Contract signed July 18, 2024; recruitment process of UNAIDS
2	TA Medical for TB and HIV	WHO	On board
3	WHO Lao country office NPO for TB and HIV	WHO	On board
4	HIV & TB TA	CHAI	On board
5	LSS TA for NCLE	CHAI	On board
6	6 staff supporting QA unit of NCLE	NCLE	On board
7	1 staff mentoring QA unit	NCLE	On board Aug 2024
8	National HIV TA	CHAS	On going (to be confirmed)

RSSH: Lab system Strengthening

	Activity		Budget	Progress	
1	Laboratory Systems Strengthening Technical Assistance	ຈັດຈ້າງຊ່ຽວຊານ ທີ່ ຮັບຜິດຊອບ ການສ້າງ ຄວາມເຂັ້ມແຂງ ດ້ານຄຸນນະພາບ ຂອງ ຫ້ອງວິເຄາະ	\$ 79,400.00	MOH approved	Contract signed
2	Establishment of QA unit (6 staff) and mentorship team (6 staff)	ການວ່າຈ້າງ 06 ຕໍາແໜ່ງ ພາຍໃຕ້ ງົບປະມານ ແກ່ການສ້າງຄວາມເຂັ້ມແຂງ ດ້ານ ຄຸນນະພາບຫ້ອງວິເຄາະ ແລະ ການສື່ສານວຽກງານວິເຄາະLSS	\$ 45,000.00	MOH approved	Contract signed
3	Contracting waste disposal contractor for inventory clean-up and physical inventory count at NCLE	ກໍາຈັດສິ່ງເສດເຫຼືອ, ອະນາໄມ ແລະ ກວດນັບ ອຸປະກອນຮັບໃຊ້ວຽກງານ ວິເຄາະຢູ່ ໃນສາງສູນວິເຄາະ ແລະ ລະບາດວິທະຍາ	LAK 143,607,100.00	MOH approved	Payment process
4	Equipment management - GXP warranty extension (3yrs) for 12 NCLE GX devices plus 54 NTC devices (Phase II)	Equipment management - GXP warranty extension (3yrs) for 12 NCLE GX devices plus 54 NTC devices	LAK 547,950.00	MOH approved	Confirmed PQ
5	Spareparts and Onsite labor cost for GXP service and Maintenance (Phase I)	Spare parts and Onsite labor cost for GXP service and Maintenance (Phase I)	\$ 32,506.00	MOH approved	Confirmed PQ
6	Joint consultative meeting and establishment of technical advisor group	ກອງປະຊຸມ ປຶກສາຫາລືຮ່ວມກັນ ແລະ ສ້າງຕັ້ງກຸ່ມທີ່ປຶກສາດ້ານວິຊາການ ຂອງ ວຽກງານເສື່ອມສານວິເຄາະການແພດ	LAK 393,586,000.00	MOH approved	Activity Conducted
7	Technical Working Group meeting to review national standard for infrastructure, tests, techniques and equipment for all laboratory levels. Titled: "Policy foundation for integrated laboratory	ກອງປະຊຸມນະໂຍບາຍພື້ນຖານສໍາລັບການປະສົມປະສານຂອງຫ້ອງວິເຄາະປີ 2024	LAK 146,558,000.00	MOH approved	Completed
8	Technical meeting and consultation on SOPs for integrated laboratory - operations, specimen management	ກອງປະຊຸມ ວິຊາການ ແລະ ປຶກສາຫາລືກ່ຽວກັບປຶ້ມຄູ່ມື (SOP) ສໍາລັບການ ເຊື່ອມສານ ໃນການຮ່ວມມືຫ້ອງວິເຄາະ, ການຄຸ້ມຄອງຕົວຢ່າງ	LAK 73,320,000.00	MOH approved	Activity Conducted
9	Certify 40 biosafety cabinets in 17 provincial hospital labs and in 6 central level labs using external certifiers	ລົງກວດສອບຍັງຍືນຕຸ້ປອດເຊື້ອ	\$ 13,810.63	MOH approved	Withdrawal Fund

Progress of close out of C19RM (HANSA1)

- Financial Closure Report: Submitted
- Financial Audit report: Pending for audit report expected to be received by Dec 20, 2024
- LFA asset verification: Jan 2025

Challenges incurred implementation over the course of HANSA II Year 1

ສິ່ງທ້າທາຍ ການແກ້ໄຂບັນຫາ

ງົບປະມານປີ 1 ຂອງແຜນງານເອດສ ແລະ ວັນນະໂຮກ ໄດ້ຮັບຊ້າ (ເຊິ່ງສືບ
ເນື່ອງຈາກ ການຮອງຮັບແຜນປະຈຳປີ ແລະ ການອະນຸມັດຈ່າຍເງິນ DLI ປີ 3
ຂອງໂຄງການຫັນສາ ໄລຍະ 1)- **ຮັບງົບປະມານ 6/2024**

ຫົວໜ່ວຍຈັດຕັ້ງປະຕິບັດ ຕ້ອງໄດ້ສຸມໃສ່ຈັດຕັ້ງປະຕິບັດ ກິດຈະກຳ ໂດຍນັ້ນ
ໃສ່ກິດຈະກຳທີ່ສະໜັບສະໜູນໃຫ້ການບັນລຸຕົວຊີ້ວັດປີ 1. ກິດຈະກຳປີ 1 ທີ່
ຈັດຕັ້ງບໍ່ທັນ ແມ່ນສັງລວມ ເພື່ອຂໍສືບຕໍ່ຈັດຕັ້ງໃນປີຖັດໄປ

ງົບປະມານປີ 2 ຈະກະກຽມແຕ່ຫົວທີ ແລະ ຂໍງົບປະມານເພື່ອອໍານວຍຄວາມ
ສະດວກໃຫ້ແຕ່ລະພາກສ່ວນ 50% ຂອງແຜນປີ

ການປ່ຽນກົນໄກ ຈັດຕັ້ງປະຕິບັດ ຈາກ DLI ມາເປັນ PBC ຂາດການຮຽນຮູ້
ແລະ ຖອດຖອນບົດຮຽນກັບຂະແໜງການອື່ນໆ ກ່ອນນຳໃຊ້ກົນໄກໃໝ່ ເຊິ່ງ
ເຮັດໃຫ້ບໍ່ມີຄວາມຈະແຈ້ງ ໃຫ້ແກ່ບັນດາຫົວໜ່ວຍຈັດຕັ້ງປະຕິບັດໂຄງການ.

- ມີການປະສານງານໃກ້ຊິດ ດ້ານວິຊາການ ແລະ ການຄຸ້ມຄອງໂຄງການ ກັບ
ຜູ້ໃຫ້ທຶນ
- ສ້າງບັນດານິຕິກຳເພື່ອເປັນບ່ອນອີງໃນການຈັດຕັ້ງປະຕິບັດ: ຄູ່ມືແນະນຳ
ການຈັດຕັ້ງປະຕິບັດໂຄງການ, ຄູ່ມືຄອງການເງິນ, ບັນດາຂໍ້ແນະນຳ ຕ່າງໆ
- ຄົ້ນຄວ້າ ເພື່ອປັບປຸງຂະບວນການອະນຸມັດເອກະສານ ກ່ອນຈັດຕັ້ງ
ປະຕິບັດກິດຈະກຳ

ການຈັດຊື້ບັນດາ HIV& TB HP ຖືກລ່າຊ້າ (ເລີ່ມຂໍໃນເດືອນ 4) ເນື່ອງຈາກ
ການເຂົ້າລົງທະບຽນ ເຂົ້າລະບົບຈັດຊື້ PPM (Wambo & GDF)

ຕິດຕາມ ການນຳສິ່ງສິນຄ້າ ແລະ ປັບປຸງໄລຍະເວລາໃນການສັ່ງຊື້ໃນປີຖັດໄປ
ເພື່ອບໍ່ໃຫ້ມີສະພາບການບິບຮັດຍ້ອນຢາຂາດ

ຢາ ແລະ ນໍ້າຢາກວດເອດ ບາງລາຍການມີການຂາດສາງ ເຮັດໃຫ້ຕ້ອງໄດ້
ປະສານງານເລັ່ງການຈັດສົ່ງ ແລະ ຈັດຊື້ຢາແບບສຸກເສີນ

ປັບປຸງການຄາດຄະເນຄວາມຕ້ອງການຢາ ແລະ ເຄື່ອງໃຊ້ສິ້ນເບື້ອງຕ່າງໆ;
ປັບປຸງຄືນແຜນການຈັດຊື້ປີ 2025-2026

Challenges incurred implementation over the course of HANSA II Year 1

ສິ່ງທ້າທາຍ

ມາດຕະຖານສິນຄ້າ ບໍ່ຖືກກຳນົດຊັດເຈນ ກ່ອນເຮັດການຈັດຊື້ ລ່າຊ້າການໄດ້
ຮັບຜະລິດຕະພັນ i.e. ລາຍການຖົງຢາງອະນາໄມ ແລະ ສານລໍ່ລິ້ນ ມີການ
ດັດແກ້ຂໍ້ຈັດຊື້ ເນື່ອງຈາກ ການອອກແບບຜະລິດຕະພັນ, ສິ່ງທຸ້ມທໍ່

ການແກ້ໄຂບັນຫາ

- ພາກສ່ວນຊົມໃຊ້ເຄື່ອງ ກຳນົດມາດຕະຖານລະອຽດ ທີ່ຕິດພັນກັບ
ຜະລິດຕະພັນໃນການຈັດຊື້ທຸກໆລາຍການ
- ຂໍ້ດັດແກ້ PQ, ຢັ້ງຢືນ ມາດຕະຖານເຕັກນິກໃຫ້ຜູ້ສະໜອງ UNFPA
- ລວມການຈັດຊື້ປີ 2024 ແລະ 2025 ເຂົ້າກັນ

ການໄຫຼວຽນເອກະສານ ສໍາລັບ PBC (ສູນກາງ)

ກົມວິຊາການ

1. Technical Division/Unit
2. Finance
3. Director

ສູນວິຊາການ

1. Admin Division
2. Technical Division
3. Director

NPCO & ກົມແຜນການ ແລະ ການເງິນ

ໜ້າສິນສະເໜີຂໍຄໍາເຫັນ

ເນື້ອໃນເອກະສານ: ສູນສະຖິຕິ ແລະ ຂ່າວສານສາທາລະນະສຸກ: ສະເໜີຄື້ນຄວ້າຈັດສັນງົບປະມານໂຄງການ ເຂົ້າໃນການຈັດພິມ
ອຸປະກອນຮັບໃຊ້ກິດຈະກຳ SBCC ສໍາລັບຂັ້ນບ້ານ ທີ່ຂະຫຍາຍໃໝ່ໃນຈໍານວນ 13 ເມືອງເປົ້າໝາຍ

ຄໍາເຫັນຂອງໜ່ວຍງານບໍລິຫານ: _____

ປະເພດກິດຈະກຳ: ຈັດກອງປະຊຸມ ອີເມວ ຈັດຊື້ ຕິດຕາມຮຸກຮຸນ ລົງເຄື່ອນໄຫວທ້ອງຖິ່ນ ອື່ນໆ

ງົບປະມານຂອງອົງປະກອບ: 1 2 3 4

ຕົວຊີ້ວັດ PBC/ Non-PBC: 1 2 3 4 5 6 7

ລະຫັດກິດຈະກຳ: _____ ມູນຄ່າກິດຈະກຳ: _____

ລດ	ເອກະສານປະກອບ	ມີ <input type="checkbox"/>	ບໍ່ມີ <input type="checkbox"/>	ຄໍາເຫັນ
1	ໜັງສືສະເໜີໂຄງການ ຫຼື ກຜງ			
2	ບົດສະເໜີໂຄງການ (Proposal)			
3	ແຜນເຄິດໄລ່ງົບປະມານລະອຽດ			
4	ຮ່າງໃບສະເໜີ ກຜງ ຫາກະຊວງ			
5	ຮ່າງຂໍ້ຕົກລົງຂອງກະຊວງ			

ຜູ້ກວດເອກະສານ: _____ ວັນທີກວດ: _____

ຄໍາເຫັນຂອງໜ່ວຍງານຕິດຕາມ ແລະ ປະເມີນຜົນ

ກິດຈະກຳມີໃນແຜນປະຈຳປີ ລະຫັດກິດຈະກຳທີ: _____ ງົບປະມານໃນແຜນປະຈຳປີ: _____

ຜົນກະທົບຕໍ່ຕົວຊີ້ວັດໂຄງການ: _____

ຄວາມສອດຄ່ອງຂອງການຂຶ້ນແຜນກິດຈະກຳ ແລະ ຜົນໄດ້ຮັບຈາກການເຄື່ອນໄຫວວຽກ/ວິຊາການ: _____

ຄໍາເຫັນຂອງໜ່ວຍງານ ຈັດຊື້-ຈັດຈ້າງ (ໃຫ້ມີຄໍາເຫັນຈ້າງວຽວຂ້ອງ): ກ່ຽວຂ້ອງ ບໍ່ກ່ຽວຂ້ອງ

ຄໍາເຫັນຂອງໜ່ວຍງານການເງິນ:

ຄໍາເຫັນຜູ້ບໍລິຫານໂຄງການ:

ຄໍາເຫັນຂອງຄະນະໂຄງການ:

ຄໍາເຫັນຂອງຫົວໜ້າກົມແຜນການ ແລະ ການເງິນ:

ຜູ້ຮັບເອກະສານສຸດທ້າຍ (ວິຊາການໂຄງການ):

ສັງລວມຄໍາເຫັນຂອງແຕ່ລະໜ່ວຍງານ

ປະສານ/ແນະນໍາ ພາກສ່ວນກ່ຽວຂ້ອງ ເພື່ອສືບຕໍ່ດໍາເນີນການ ວັນທີ _____ (ຊື່) _____


ບັນທຶກ ຂໍ້ມູນລົງໃນການຕິດຕາມຂອງໂຄງການ

ເອກະສານມອບໃຫ້ _____ ວັນທີ _____ ລາຍເຊັນ _____

ກະຊວງສາທາລະນະສຸກ

1. Admin division
2. Secretariat division
3. Minister Decision

ການໄຫຼວຽນເອກະສານ ສໍາລັບ PBC (ທ້ອງຖິ່ນ)



Management and Coordination Continuation

Budget Plan for 2025

Modality	Implementing Agencies	Activities	Procurement	Total
IBF 1	NCLE	67,034	568,312	635,346
PBC 6	CHAS	949,843	1,157,497	2,107,340
PBC 7	NTC	944,734	1,026,073	1,970,807
		1,961,611	2,751,883	4,713,494

2025 Implementation Preparation

- Received AWPB 2025 and AOP from PBC6 & PBC7 and submit for donor review and No-Objection
 - Forward AOP to MOH for adoption
- Received NOL for PBC Y2 50% advance of the PBC Y2 value
 - Proceeded fund request process with MOF
 - To Obtain fund transfer approval from MOH & MOH

Procurement 2025:

- Update procurement plan (after GF review)
- CHAS & NTC to submit Request letter for procurement
- NPCO to Raise requisition

Mission follow up (agreed actions): now- Dec 2024

- Progress update
- Support on coordination

Thank You!

